ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ponesimod

Also written as “Ponesimod”, “ACT-128800” and “Ponesimod 10 mg”.

Its studies are mostly in Multiple Sclerosis · Psoriasis · Colitis, Ulcerative · Bronchiolitis Obliterans Syndrome, led by 2 companies.

Drug pagePonesimod: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 21, 201516 company-led studies, 2 open or runningNext primary completion: Aug 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only140 open or runningphase 3since Apr 21, 2015Feb 26, 2009none ahead
Vanda Pharmaceuticals22 open or runningphase 3since Jan 20, 2026Jan 20, 2026Aug 2028phase 3 · NCT07362017

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Vanda Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 20, 2026First study: phase 3 study in PsoriasisFirst studyNCT07362017 · 300 planned · United States
  2. Jun 30, 2026Phase 3 study in Colitis, UlcerativeNCT07686081 · 150 planned · United States

Ahead

  1. Aug 2028Primary completion: phase 3 study in PsoriasisNCT07362017
  2. Apr 2029Primary completion: phase 3 study in Colitis, UlcerativeNCT07686081

TargetBeta

S1PR1 →read by rule
“An orally available sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) agonist that acts as a functional antagonist, ”NCIt, by rule
“Sphingosine 1-phosphate receptor Edg-1 agonist”ChEMBL 37, by rule

Other programs on S1PR1

ProgramCompanyFurthest phaseStudies
fingolimodruleNovartisphase 455
etrasimodrulePfizerphase 321
cenerimodruleViatrisphase 314
mocravimodruleNovartisphase 35

Studies

All 2 Vanda Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07686081Colitis, Ulcerative · United States3RecruitingApr 2029150
NCT07362017Psoriasis · United States3RecruitingAug 2028300

How it is read

Names in the registry

  • “Ponesimod”, 6 entries
  • “ACT-128800”, 5 entries
  • “Ponesimod 10 mg”, 2 entries
  • “Ponesimod 20 mg”, 2 entries
  • “Ponesimod 40 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.